In other tumor subtypes, such as non–small cell lung cancer, evidence suggests that anti–PD-1 agents could be more effective than anti–PD-L1 agents, as anti–PD-1 agents simultaneously block PD-1 binding with both PD-L1 and PD-L2.4 However, anti–PD-L1 agents did not influence the PD-1–PD-L2 interaction, which may inhibit T-cell activation. Here, PDCD1 is linked to neoplasm.